Results: Of the 354 samples tested, 74 individual cases were PCR positive. A result from the treponemal antibody chemiluminescent microparticle immunoassay test was positive in 72 of these cases and that from the Venereal Disease Research Laboratory testing was positive in 66. Mutations conferring resistance to azithromycin were found in all 74 PCRpositive samples. Molecular typing was completed on 57 PCR-positive samples, and 12 molecular types were identified with 14d/g found in 63.2%. Increased strain diversity was observed with 8 molecular types detected in 2016, whereas only 2 to 3 types were found in 2012 to 2014. A patient with 2 episodes of infection 9 months apart caused by different molecular strain types was also identified.
Conclusions:
The finding of an increase in genetic diversity in the strains in this study and an increase in macrolide resistance compared with previous Canadian reports highlighted the need for continued surveillance including strain characterization.
T reponema pallidum subspecies pallidum (T. pallidum), the causative agent of venereal syphilis, is a spirochete that cannot be cultured by traditional bacteriological techniques. Therefore, laboratory diagnosis of syphilis is based on serology or direct detection of the organisms by microscopy (dark-field or fluorescent antibody). Detection of T. pallidum-specific genes, polA, tpp47, and bmp, can be done by polymerase chain reaction (PCR).
1,2 Serological tests for syphilis are divided into nontreponemal and treponemal tests. Rapid plasma reagin and Venereal Disease Research Laboratory (VDRL) detect nontreponemal antibodies (or reagins) in patient serum produced as a result of syphilis infections and some nontreponemal diseases. Tests detecting treponemal antibodies include T. pallidum particle agglutination test, fluorescent treponemal antibody absorption test, and several variations on enzyme immunoassays, such as chemiluminescent microparticle immunoassay (CMIA), which detect antibodies against recombinant T. pallidum antigens.
In the last 2 decades, several developed countries, including Canada and the United States, have reported a resurgence in syphilis diagnoses, mainly among men who have sex with men (MSM). [3] [4] [5] [6] The US Centers for Disease Control and Prevention (CDC) recommends intramuscular injection of benzathine penicillin G as the first-line treatment of syphilis. 7, 8 Azithromycin (an oral macrolide antibiotic with a long half-life) treatment and chemoprophylaxis (given to contacts of syphilis cases) began in both San Francisco, California, and Vancouver, British Columbia, in 1999 to 2000 to combat increased rates of syphilis and to limit the spread of disease. 5 Soon after, azithromycin treatment failures occurred and the first reports of azithromycin-resistant syphilis infections began in 2002 to 2003. 9 Since then, increased prevalence of macrolide resistance in T. pallidum has been observed in several countries. 10 Azithromycin-resistant T. pallidum strains were reported to have either the A2058G 11 or the A2059G 12 mutations in both copies of the 23S rRNA genes. To date, there have been no reports of strains possessing both mutations.
The CDC molecular typing scheme used to distinguish subtypes of T. pallidum strains is based on the number of 60-base-pair tandem repeats in the acidic repeat protein (arp) gene and restriction fragment length polymorphism (RFLP) analysis of the T. pallidum repeat (tpr) genes. 13 In addition, the enhanced typing scheme involves partial gene sequencing of the tp0548 gene 14 (e.g., 14d/g, meaning 14 arp repeats, tpr RFLP pattern d, and tp0548 group g).
The province of Manitoba resides in the longitudinal center of Canada and has a population of approximately 1.3 million. The province is split into 5 health regions: Northern, covering the northern half of the province; Prairie Mountain Health, covering southwestern Manitoba; Interlake Eastern, covering Southeastern Manitoba; Southern Health, covering South-central Manitoba; and the Winnipeg Health Region, covering the capital city of Winnipeg and the town of Churchill in northern Manitoba. In this study, as part of a public health-enhanced surveillance activity, we analyzed PCR-positive syphilis cases in Manitoba, Canada, from 2012 to 2016 to characterize T. pallidum strains by molecular type and to determine the prevalence of macrolide resistance among circulating strains.
MATERIALS AND METHODS

Clinical Specimens
From January 1, 2012, to December 31, 2016, a total of 354 clinical specimens from individual disease cases were submitted for routine laboratory diagnostic PCR testing for infectious syphilis in Manitoba, Canada. All specimens were serologically positive and were received through the provincial public health laboratory, originating mainly from sexually transmitted infection clinics as well as some from infectious disease clinics and general practices. Most specimens were swabs (mainly from suspected primary and occasionally secondary syphilitic lesions; n = 349), followed by cerebrospinal fluid (n = 2), dried blood spot (n = 2), and whole blood (n = 1).
DNA Extraction and PCR Methods
Extraction of DNA from clinical specimens was performed using the QIAmp DNA Mini kit (Qiagen, Toronto, Ontario, Canada). Polymerase chain reaction detection of T. pallidum gene targets tpp47, bmp, and polA was performed as previously described using the HotStar Taq DNA Polymerase kit (Qiagen) and were considered PCR positive if 2 or more targets were amplified. 15 
Detection of Macrolide Resistance
Polymerase chain reaction amplification and partial gene sequencing of the 23S rRNA gene for detection of mutations conferring macrolide resistance was performed using previously described PCR primers and conditions. 15 The PCR products were purified using DIFFINITY RapidTip (Diffinity Genomics, West Chester, PA) and sequenced on the Applied Biosystems 3730xl DNA Analyser system (Applied Biosystems, Foster City, CA). Sequences from both strands of DNA were examined using software from DNAStar, Lasergene 11 Core Suite (DNAStar Inc, Madison, WI) and designated as macrolide resistant if the A2058G or A2059G mutations were present.
11,12
Molecular Subtyping Molecular typing of PCR-positive syphilis cases was done by determining the number of repeats in the arp genes, RFLP pattern of the tpr genes after restriction enzyme digest with MseI, 13 and partial sequence analysis of the tp0548, as previously described.
14,16
Serological Testing
Venereal Disease Research Laboratory testing was carried out as per manufacturer's instructions using the BD VDRL Antigen for syphilis Serology and BD Difco VDRL Test Control Serum Set (Becton Dickinson, Sparks, MD). Samples were designated reactive or nonreactive based on microscopic examination of flocculation in comparison with control sera, and if reactive, the highest dilution showing flocculation was recorded. Chemiluminescent microparticle immunoassay testing was carried out using the ARCHITECT Syphilis TP Assay as per the manufacturer's instructions (Abbott Diagnostics, Mississauga, Ontario, Canada), and samples were considered positive if the relative light unit, which was directly proportional to the amount of treponemal antibodies present in the sample, was greater than or equal to a predetermined signalto-cutoff ratio of 1, per product insert.
Statistical Analysis
Statistical analysis was done following methods described by Hill. 17 Because there were no PCR-positive syphilis cases between 2007 and 2012 and there were 1012 new syphilis serological diagnoses in Manitoba between 2012 and 2016, with a margin of error of 5%, confidence level of 95%, and presumed response distribution of 50%, a sample size of 354 used in this study was deemed reasonable and representative.
RESULTS
Of the 354 clinical specimens tested for syphilis by PCR, there were 74 positive cases (Table 1 ). There were 14 cases in female patients (18.9%) and 60 cases in male patients (81.1%). Two of the positive samples were from an individual with a reinfection due to different molecular types, and the 2 positive samples were recovered 9 months apart. There were 52 cases (70.2%) in urban areas and 22 cases (29.8%) in rural Manitoba. The age of the patients ranged from 1 month to 70 years, and 41.9% of the PCR-positive syphilis cases occurred in men aged 18-35 years (Fig. 1) . Most PCR-positive syphilis cases (73/74; 98.6%) were detected in swab specimens from anogenital (66/73; 90.4%) or oropharyngeal (7/73; 9.6%) ulcers, whereas the remaining PCR-positive case was from a dried blood spot specimen taken from a 1-month-old patient with congenital syphilis.
Partial DNA sequencing on the 23S rRNA gene found that previously identified mutations conferring macrolide resistance, A2058G (n = 72) or A2059G (n = 2), were present in all PCRpositive specimens.
Molecular typing was completed on 57 PCR-positive specimens, and 12 different molecular types were found (Table 1) . Typing could not be completed on 17 specimens because of insufficient sample quantity, including the congenital syphilis case. The most common molecular type was 14d/g, which was observed in 36 cases (63.2%) ( Table 1 ). Molecular types 14p/g and 14f/g were observed in 4 cases each (7.0%), followed by 14j/g (n = 3; 5.3%), 14b/g and 14k/g (n = 2 each; 3.5%), and 9d/g, 9f/g, 14d/ f, 14d/j, 14j/c, and 14l/g (n = 1 each; 1.8%; Table 1 ).
In conjunction with PCR detection for syphilis, serological testing was also performed. Among the 74 PCR-positive cases, CMIA results were positive in 72 cases and negative in 1 case, and there was 1 case from 2012 that was not tested, because CMIA was not part of routine testing at that time. Results from the VDRL testing for these 74 PCR-positive cases varied from nonreactive (n = 8) to reactive at titers of ≥8 (n = 50; with median titer of 32), and also 16 cases were reactive with titers between 1 and 4.
DISCUSSION
Syphilis in Manitoba is an important health concern because of the recent widespread reports of increasing number of cases and the return of a confirmed congenital syphilis case after it had been virtually eliminated in the province for more than 2 decades. The congenital syphilis case occurred in a 1-month-old male patient residing in a rural community. His CMIA result was positive as was VDRL with a titer of 64, but the molecular type could not be determined because of insufficient sample quantity.
Although the 74 PCR-positive cases occurred from 2012 to 2016, it is important to note that more than 75% (n = 56) occurred in the last 2 years. Besides an increase in syphilis cases, less common clinical presentations have also been noted in the last few years as we previously reported, including a case with an oral lesion involving the lip 18 and a case of tonsillar syphilis. 19 According to the Manitoba Health Web site, 20 there were 17 syphilis cases reported in 2011 and 143 cases in 2015, representing both PCRpositive and serologically confirmed cases. Also, all 5 health regions covering the entire province of Manitoba, as well as jurisdictions under Health Canada's First Nations and Inuit Health Branch, reported syphilis cases in 2015. 20 In 2016, there were 326 serologically confirmed syphilis cases, including 272 that were VDRL reactive, indicating active infections (authors' unpublished data). In urban areas, syphilis infections were primarily found in MSM, whereas in the Northern areas of the province, cases in heterosexual women were more prevalent and represented up to 20% of new infections. 20 In this study, information on sexual preference was not disclosed on laboratory requisitions. Of the 14 female cases in this study, 4 (28.6%) were from rural communities (Fig. 1) . Of these 14, 13 (92.9%) were between 15 and 45 years of age.
A recent review paper listed 14d/f as the most common molecular type found globally, followed by 14d/g. 10 Only 1 case in this study was typed as 14d/f, whereas 36 were typed as 14d/g (Table 1 ), including 2 tonsillar syphilis cases. 19 The previously described case with lesion on the lip 18 could not be typed because of insufficient specimen. Predominance of 14d/g type has also been observed in London, Dublin, Paris, and Australia, where most syphilis cases occur among MSM. 10, 16 In this study, prevalence In this study, the rate of macrolide resistance in PCR-positive syphilis cases was 100% and was consistent with other reports that found that the A2058G mutation conferring macrolide resistance was more common than A2059G. 10, 21 Rates of macrolide resistance in Manitoba before 2007 were not available; however, the finding of 100% macrolide resistance is a significant increase compared with previous Canadian studies that found 2.1% and 44.4% macrolide resistance in the province of British Columbia in 2000-2003 and 2004, respectively. 22 Another Canadian study in Alberta and Northwest Territories found only 16.3% macrolide resistance in PCR-positive syphilis cases from 2007 to 2009. 15 High rates of macrolide resistance have also been reported in China, Australia, the United Kingdom, and the United States. 10, 16 However, the prevalence of azithromycin-resistant syphilis strains varied globally, with some countries either reporting low levels of macrolide resistance or having no reports of macrolide-resistant syphilis cases. 10, 21, 23, 24 Also noted was increased diversity among typeable strains. In the years 2012 to 2014, only 2 or 3 different molecular types were observed each year, which increased to 5 in 2015 and 8 in 2016, including 2 cases infected with syphilis strains that had only 9 repeats in their arp genes, 1 in an urban area and 1 in a rural area. Although travel histories were not available for these cases, it is possible that these patients were infected with the arp9 syphilis strains as a result of international travel because arp9 is relatively rare and has only been reported in syphilis cases from Taiwan. 10, 25 Another interesting finding in this study was 2 PCR-positive samples from the same patient, taken 9 months apart, with syphilis strains exhibiting different molecular types: 14j/c in November 2015 and 14d/g in August 2016. In 2015, this patient was determined to have high sexual risk factors and tested negative by rapid plasma reagin and weak positive CMIA, but reactive T. pallidum particle agglutination, and was treated in the very early stages of infection. These conditions may explain the reinfection with the predominant outbreak strain, further suggesting that even partial immunity to T. pallidum infection may not protect against infection by different stains. This notion needs corroborating.
The limitations of this study are the small number of samples tested each year as well as the lack of clinical data to link cases and monitor the potential spread of certain molecular types. The current CDC typing system has also been shown to lack reproducibility because strains may change molecular type (especially tpr type) during infection, and therefore, a more robust system based on gene sequence analysis may provide more discriminatory power. 10 However, the resurgence of syphilis in recent years, the less common manifestations such as tonsillitis and lesion involving the lip, and the increasing diversity in the molecular types of syphilis strains highlight the need for continued surveillance and molecular characterization of syphilis infections in Manitoba and in other regions. More studies are needed to investigate potential links between dominant outbreak molecular types to increased transmissibility and/or pathogenicity that will eventually inform public health response.
